Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
- ABL1 SNX2-ABL1 Fusion
- Associated Disease
- Pediatric B-cell Acute Lymphoblastic Leukemia
- Source Database
- CIViC Evidence
- Description
- A 7-yr-old boy with B-cell precursor acute lymphoblastic leukemia was found to harbor the SNX2-ABL1 fusion gene. After first relapse the patient was given imatinib at a dose of 240 mg/m2/d once daily and his disease stabilized. The patient received dasatinib (80 mg/m2/d once daily) after an umbilical cord blood transplant and did not respond to treatment. Patient was put back on imatinib at a dose of 600 mg/m2/d once daily which rapidly decreased the number of blast cells. However, the patient eventually died of disease.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7241
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2678
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Pediatric B-cell Acute Lymphoblastic Leukemia
- Evidence Direction
- Supports
- Drug
- Dasatinib
- Evidence Level
- C
- Clinical Significance
- Resistance
- Pubmed
- 24215620
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Dasatinib | Resitance or Non-Reponse | true |